The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated